191 related articles for article (PubMed ID: 25870069)
41. Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials.
Davis CB; Bambal R; Moorthy GS; Hugger E; Xiang H; Park BK; Shone AE; O'Neill PM; Ward SA
J Pharm Sci; 2009 Jan; 98(1):362-77. PubMed ID: 18563832
[TBL] [Abstract][Full Text] [Related]
42. Treatment of acute vivax malaria with tafenoquine.
Nasveld P; Kitchener S
Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):2-5. PubMed ID: 15550254
[TBL] [Abstract][Full Text] [Related]
43. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
44. A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.
Bachhav SS; Taylor M; Martin A; Green JA; Duparc S; Rolfe K; Sharma H; Tan LK; Goyal N
Br J Clin Pharmacol; 2023 Mar; 89(3):1187-1197. PubMed ID: 36199201
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.
Vielnascher E; Spatzenegger M; Mayrhofer A; Klinger P; Jäger W
Pharmazie; 1996 Aug; 51(8):586-8. PubMed ID: 8794469
[TBL] [Abstract][Full Text] [Related]
47. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
48. Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis.
Edstein MD; Nasveld PE; Kocisko DA; Kitchener SJ; Gatton ML; Rieckmann KH
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):226-30. PubMed ID: 16814823
[TBL] [Abstract][Full Text] [Related]
49. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.
Ganesan S; Tekwani BL; Sahu R; Tripathi LM; Walker LA
Toxicol Appl Pharmacol; 2009 Nov; 241(1):14-22. PubMed ID: 19616568
[TBL] [Abstract][Full Text] [Related]
50. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.
Brueckner RP; Lasseter KC; Lin ET; Schuster BG
Am J Trop Med Hyg; 1998 May; 58(5):645-9. PubMed ID: 9598455
[TBL] [Abstract][Full Text] [Related]
51. Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity.
Thelingwani R; Bonn B; Chibale K; Masimirembwa C
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1313-24. PubMed ID: 25219629
[TBL] [Abstract][Full Text] [Related]
52. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
54. The gender-related variability in the pharmacokinetics and antiplasmodial activity of naphthoquine in rodents.
Xie Y; Liu H; Sun Y; Xing J
Malar J; 2020 Feb; 19(1):71. PubMed ID: 32054478
[TBL] [Abstract][Full Text] [Related]
55. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Zourková A; Hadasová E
Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
[TBL] [Abstract][Full Text] [Related]
56. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
Shulman RW; Ozdemir V
Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
[TBL] [Abstract][Full Text] [Related]
57. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
58. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
D'Empaire I; Guico-Pabia CJ; Preskorn SH
J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
[TBL] [Abstract][Full Text] [Related]
59. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
[No Abstract] [Full Text] [Related]
60. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
